Table 3.
Characteristics of non-black men with low, borderline and high levels of preoperative serum cholesterol
| Low cholesterol (<200 mg/dl) (n=669; 65%) | Borderline cholesterol (200–239 mg/dl) (n=282; 28%) | High cholesterol (≥240 mg/dl) (n=69; 7%) | p-value | |
|---|---|---|---|---|
| Age, mean ± SD | 62.5 (5.6) | 62.1 (6.2) | 62.2 (5.7) | 0.671 |
|
| ||||
| Year of surgery, median (Q1–Q3) | 2009 (2005–2011) | 2007 (2003–2011) | 2008 (2003–2011) | <0.001 |
|
| ||||
| Follow-up (years), median (Q1–Q3) | 2.4 (0.9–4.5) | 2.7 (0.8–6.2) | 2.5 (1.5–6.2) | 0.166 |
|
| ||||
| PSA (ng/ml), median (Q1–Q3) | 6.0 (4.6–8.3) | 6.9 (5.1–10.5) | 6.1 (4.3–8.0) | 0.001 |
|
| ||||
| Pathological Gleason score, n (%) | ||||
| 2−6 | 170 (25) | 90 (32) | 21 (30) | 0.067 |
| 7 (3+4) | 244 (36) | 94 (33) | 31 (45) | |
| 7 (4+3)−10 | 255 (38) | 98 (35) | 17 (25) | |
|
| ||||
| Positive margins, n (%) | 236 (35) | 104 (37) | 29 (42) | 0.517 |
|
| ||||
| Extracapsular extension, n (%) | 125 (19) | 70 (25) | 14 (20) | 0.101 |
|
| ||||
| Seminal vesicle invasion, n (%) | 60 (9) | 26 (9) | 4 (6) | 0.651 |
|
| ||||
| Positive lymph nodes, n (%) | 12 (2) | 9 (3) | 0 (0) | 0.301 |
|
| ||||
| BMI (kg/m2), median (Q1–Q3) | 28.3 (25.5–31.2) | 28.0 (25.4–30.9) | 27.1 (24.2–30.4) | 0.147 |
|
| ||||
| Diabetes, n (%) | 50 (14) | 21 (13) | 4 (11) | 0.937 |
|
| ||||
| LDL (mg/dl), mean ± SD | 98.8 (21.8) | 135.8 (21.3) | 174.2 (26.8) | <0.001 |
|
| ||||
| HDL (mg/dl), mean ± SD | 42.4 (12.3) | 48.2 (17.8) | 50.6 (21.2) | <0.001 |
|
| ||||
| Triglycerides (mg/dl), mean ± SD | 131.3 (77.4) | 157.9 (86.4) | 214.2 (263.2) | <0.001 |
|
| ||||
| Statin use, n (%) | ||||
| Never use | 580 (87) | 209 (74) | 50 (72) | <0.001 |
| Postoperative use | 89 (13) | 73 (26) | 19 (28) | |
BMI=body mass index; HDL=high-density lipoprotein; LDL=low density lipoprotein; PSA=prostate specific antigen; SD=standard deviation; Q1=25th percentile; Q3=75th percentile